Evicenter
MarkdownMedical informationP&T meetings
VK2735

Chronic weight management

Last updated
184 sources

Executive summary

VK2735 efficacy and safety

3 evidence topics · 17 sources

Summary: subcutaneous formulation

In the phase 2 VENTURE trial, 176 participants with obesity, or overweight with a weight-related comorbidity, and without diabetes were randomized to placebo or once-weekly subcutaneous VK2735 at 2.5, 5.0, 10, or 15 mg for 13 weeks. In the peer-reviewed publication, the least squares mean percent change in body weight from baseline to week 13 in the modified intent-to-treat population (mixed model for repeated measures) was −9.1% (2.5 mg), −10.9% (5.0 mg), −12.9% (10 mg), and −14.7% (15 mg), compared with −1.7% for placebo, with placebo-adjusted differences of −7.43 to −13.08 percentage points (p < 0.0001 for each dose). Weight reduction of at least 10% occurred in 40.1% to 89.1% of participants across the VK2735 arms and 3.0% with placebo; the topline press release reported 39% to 88% and 4%. The topline release reported no weight-loss plateau at week 13. Of 74 participants with prediabetes at baseline in the active arms, 58 (78%) were normoglycemic at week 13.

In the VENTURE safety population (175 participants), discontinuation of study drug due to a treatment-emergent adverse event occurred in 0 of 35 participants with placebo and in 1 (3%), 4 (11%), 4 (11%), and 7 (20%) of 35 participants at 2.5, 5.0, 10, and 15 mg. The most common drug-related events were nausea (36.6%), constipation (21.1%), and vomiting (12.6%), and gastrointestinal events were reported mainly early in treatment. Eight participants (4.6%) had 12 serious adverse events, 2 of which, in 1 participant, were considered drug-related; 1 death (head trauma from a fall) was assessed as unrelated. Mean heart rate increased by 3.3 to 9.3 bpm across the VK2735 arms and by 1.4 bpm with placebo, and anti-drug antibodies were detected in 9% to 23% of participants at week 13. No pancreatitis was reported.

In Part 1 of the phase 1 VK2735-102 maintenance study, reported in a press release, weight loss after 21 weeks of weekly dosing (15 to 22.5 mg) was 16.3% to 18.7% from baseline, compared with 0.1% for placebo. Over the following 12 weeks, participants switched to every-other-week dosing retained 83% to 97% of their week 21 weight loss and those switched to monthly dosing retained 82% to 90%, compared with 61% for participants switched to placebo. During induction, 22 of 166 VK2735-treated participants (13%) discontinued treatment early and 1 (1%) discontinued due to an adverse event. In the 28-day multiple ascending dose part of the phase 1 VK2735-101 study, mean body weight decreased by up to 7.8% from baseline (up to 6.0% relative to placebo); one serious adverse event (acute choledocholithiasis) occurred in a participant with a history of cholelithiasis.

Summary: oral formulation

In the phase 2 VENTURE-Oral Dosing trial, 280 participants were randomized to placebo, once-daily oral VK2735 at 15, 30, 60, 90, or 120 mg, or an exploratory cohort that received 90 mg and then 30 mg, for 13 weeks. Results are available in a topline press release, a congress poster, and company presentations; no peer-reviewed publication was identified. The least squares mean percent change in body weight at week 13 was −2.3%, −7.0%, −8.7%, −11.1%, and −12.2% at 15, 30, 60, 90, and 120 mg, compared with −1.3% for placebo (placebo-adjusted −1.0% to −10.9%); differences from placebo were statistically significant for doses above 15 mg. Weight loss of at least 10% occurred in 8% to 80% of participants across the dose arms and 5% with placebo. The exploratory cohort reached −9.2% at week 13 after transition from 90 mg to 30 mg.

Treatment discontinuation was 18% with placebo and 20% to 38% across the fixed-dose arms (38% at 120 mg), and discontinuation of treatment due to a treatment-emergent adverse event was 13% with placebo and 5% to 30% across the dose arms (30% at 120 mg). The release reported pooled rates of 28% for any treatment discontinuation and 20% for discontinuation due to an adverse event with VK2735. Nausea was reported in 58% of VK2735-treated participants and 48% with placebo, and vomiting in 26% and 10%; the company attributed discontinuations mainly to gastrointestinal adverse events and stated that the titration rate likely affected the gastrointestinal profile. The poster reported drug-related serious adverse events in 1 participant at 60 mg and in participants at 120 mg. Pharmacokinetic results from this trial have not been reported.

In the 28-day oral cohorts of the phase 1 VK2735-101 study (2.5 to 100 mg daily), mean body weight decreased by up to 8.2% from baseline (up to 6.8% relative to placebo). The congress poster reports 1 serious adverse event in the 60 mg cohort (1 of 9 participants), and an earlier interim release covering doses through 40 mg reported none.

Summary: ongoing phase 3 trials

Four phase 3 trials are underway, and none has reported results. The subcutaneous VANQUISH-1 and VANQUISH-2 trials are randomized, double-blind, placebo-controlled trials of once-weekly VK2735 7.5, 12.5, or 17.5 mg for 78 weeks. VANQUISH-1 enrolled adults without type 2 diabetes with obesity (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) with at least one weight-related comorbidity; the November 2025 enrollment release reported approximately 4,650 participants, and later company documents report approximately 4,500. VANQUISH-2 enrolled approximately 1,000 adults with type 2 diabetes and obesity or overweight. The primary endpoint of each is the percent change in body weight from baseline compared with placebo after 78 weeks, and the company expects data in the second half of 2027.

The oral SUNRISE-1 and SUNRISE-2 trials are randomized, double-blind, placebo-controlled trials of once-daily oral VK2735 27.5, 35, or 55 mg for 68 weeks, each targeting 560 adults; SUNRISE-2 enrolls adults with type 2 diabetes. The company announced their initiation in October 2026, while the registry records listed both as “Not yet recruiting”. The company expects SUNRISE data in 2028.